Uwe Schoenbeck leads Pfizer’s External Science & Innovation (ES&I) team, which is responsible for enhancing Pfizer’s Worldwide R&D pre-clinical and clinical pipeline by introducing novel targets, prosecuting externally sourced cutting edge science through partnership with academia, and harnessing innovative assets and breakthrough technologies through partnerships with Biotech and Pharma.
ES&I is composed of three key pillars: a global External Search & Evaluation and Venture Investment team working across Pfizer’s therapeutic priority areas and sourcing transformative assets and technologies via scouting, seed funding, and NewCo formation; a team focused on novel target and biology discovery research to help drive rejuvenation of the pipeline and enhance Confidence in Rational in our programs; and the Centers for Therapeutic Innovation (CTI), a global externally-networked academic partnership for drug co-development. This end-to-end innovation capability aims to strengthen Pfizer’s research engine and be a key driver of a pipeline of truly differentiated first-in-class pipeline assets as well as breakthrough technologies by effectively combining external innovation with Pfizer’s internal drug development capabilities.
Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team and Senior Leadership Committee. Prior to joining the company, he served as Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position with Brigham & Women’s Hospital, Harvard Medical School. Uwe has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in molecular & cell biology, cardiovascular research, immunology, and metabolism.